Last Updated: November 16, 2026

Investigational Drug Information for AG-881

« Back to Dashboard


What is the drug development status for AG-881?

AG-881 is an investigational drug.

There have been 11 clinical trials for AG-881. The most recent clinical trial was a Phase 1 trial, which was initiated on October 18th 2024.

The most common disease conditions in clinical trials are Glioma, Liver Diseases, and Hematologic Neoplasms. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., Institut de Recherches Internationales Servier, and Merck Sharp & Dohme LLC.

There are four hundred and forty-three US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for AG-881
TitleSponsorPhase
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 MutationServierPHASE3
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic FunctionInstitut de Recherches Internationales ServierPhase 1
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant AstrocytomasMerck Sharp & Dohme LLCPhase 1

See all AG-881 clinical trials

Clinical Trial Summary for AG-881

Top disease conditions for AG-881
Top clinical trial sponsors for AG-881

See all AG-881 clinical trials

US Patents for AG-881

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-881 ⤷  Start Trial Compositions and methods for treating conditions of compromised skin barrier function Shiseido Co Ltd ⤷  Start Trial
AG-881 ⤷  Start Trial Biguanide compositions and methods of treating metabolic disorders ELCELYX THERAPEUTICS, INC. (San Diego, CA) ⤷  Start Trial
AG-881 ⤷  Start Trial Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Start Trial
AG-881 ⤷  Start Trial Enhanced efficiency of sunscreen compositions Beiersdorf AG , Nouryon Chemicals International BV , Coppertone LLC ⤷  Start Trial
AG-881 ⤷  Start Trial Compositions containing HC-HA/PTX3 complexes and methods of use thereof TISSUETECH, INC. (Miami, FL) ⤷  Start Trial
AG-881 ⤷  Start Trial Oral care composition Colgate Palmolive Co ⤷  Start Trial
AG-881 ⤷  Start Trial Use of benzyl alcohol as a defoaming agent Colgate Palmolive Co ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-881

Drugname Country Document Number Estimated Expiration Related US Patent
AG-881 Australia AU2012312170 2031-09-21 ⤷  Start Trial
AG-881 Canada CA2848943 2031-09-21 ⤷  Start Trial
AG-881 European Patent Office EP2758032 2031-09-21 ⤷  Start Trial
AG-881 Russian Federation RU2014115845 2031-09-21 ⤷  Start Trial
AG-881 World Intellectual Property Organization (WIPO) WO2013044098 2031-09-21 ⤷  Start Trial
AG-881 Argentina AR091089 2031-01-07 ⤷  Start Trial
AG-881 Argentina AR091739 2031-01-07 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

AG-881 Vorasidenib Development Update and Market Projection

Last updated: September 4, 2026

AG-881, now called vorasidenib and marketed in the United States as Voranigo, is an oral dual inhibitor of mutant IDH1 and IDH2 developed by Agios Pharmaceuticals and acquired by Servier. The drug received FDA approval on Aug. 6, 2024, for adults and adolescents aged 12 years and older with grade 2 astrocytoma or oligodendroglioma carrying susceptible IDH1 or IDH2 mutations after surgery, including biopsy, subtotal resection, or gross total resection.[1]

Vorasidenib is the first FDA-approved therapy specifically directed at IDH-mutant diffuse glioma. Its commercial opportunity is concentrated in a molecularly defined, relatively small brain-tumor population. A base-case U.S. peak-sales estimate of approximately $500 million to $800 million is reasonable, with upside toward $1 billion if treatment duration is long, international approvals expand, and use moves into earlier-line or combination settings.

What is the current development status of AG-881?

Vorasidenib has completed development in the initial target population and is commercially available in the United States.

FDA regulatory milestones

Milestone Date Status
AG-881 entered clinical development 2010s Completed
Phase 1 dose-escalation and expansion studies 2010s Completed
Phase 3 INDIGO study initiated 2020 Completed
FDA Breakthrough Therapy designation 2023 Granted
NDA accepted for priority review 2024 Completed
FDA approval as Voranigo Aug. 6, 2024 Approved
Initial indication 2024 Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery
Dosage form 2024 Oral tablets, 10 mg and 40 mg
Recommended adult and adolescent dose 2024 40 mg once daily

The approved indication is narrower than the entire IDH-mutant glioma market. Vorasidenib is indicated after surgery when immediate radiation and chemotherapy are not required. The FDA label specifies that treatment should continue until disease progression or unacceptable toxicity.[1]

What did the INDIGO trial show?

The pivotal INDIGO trial was a randomized, double-blind, placebo-controlled Phase 3 study involving 331 patients with residual or recurrent grade 2 IDH-mutant glioma. Patients had undergone surgery but had not yet received radiation or chemotherapy.

The primary endpoint was progression-free survival. Vorasidenib produced a median progression-free survival of 27.7 months compared with 11.1 months for placebo. The hazard ratio for disease progression or death was 0.39.[2]

The study also showed a delay in the time to the next intervention:

Endpoint Vorasidenib Placebo
Median progression-free survival 27.7 months 11.1 months
Hazard ratio 0.39 Reference
Median time to next intervention 17.8 months at interim analysis 11.4 months
IDH mutation target IDH1 or IDH2 N/A

The clinical value is tied to delaying radiation and cytotoxic chemotherapy. That positioning may improve adoption among patients and physicians seeking to preserve neurocognitive function and defer treatment-related toxicity.

What is the FDA status and Orange Book position for Voranigo?

Voranigo is FDA-approved and subject to the standard U.S. prescription-drug regulatory framework. The FDA granted regular approval based on the INDIGO results rather than accelerated approval.[1]

What is the approved use?

The approved population consists of patients with:

  • Grade 2 astrocytoma or oligodendroglioma
  • A susceptible IDH1 or IDH2 mutation
  • Age 12 years or older
  • Prior surgery, biopsy, subtotal resection, or gross total resection
  • No prior radiation or systemic chemotherapy for the current disease setting

The drug requires molecular confirmation of IDH status. This makes diagnostic testing a commercial prerequisite. The relevant testing market includes next-generation sequencing panels and immunohistochemistry for common IDH1 mutations.

Orange Book and patent information

FDA approval does not by itself establish a single, permanent generic-entry date. The commercial exclusivity analysis depends on listed patents, pediatric exclusivity, regulatory exclusivity, patent-term adjustment, and any Paragraph IV litigation.

Voranigo received seven years of orphan-drug exclusivity in the United States, which generally protects the approved orphan indication through August 2031, subject to statutory exceptions.[1] The approval also carries five years of new chemical entity exclusivity unless the product qualifies for other applicable extensions.

The core patent estate is expected to include composition-of-matter, therapeutic-use, and pharmaceutical-composition claims. Publicly available patent records should be reviewed against the FDA Orange Book for current patent numbers, expiration dates, and any pediatric patent-term extension before making a launch decision. The principal commercial protection is likely to extend beyond the five-year NCE period through issued patent claims, but the exact generic-entry date depends on the patents listed for Voranigo and the outcome of any Paragraph IV challenge.

When does vorasidenib lose exclusivity?

The earliest practical U.S. generic-entry window is unlikely to be before the early 2030s for the approved orphan indication.

Protection Approximate end point Commercial effect
New chemical entity exclusivity 2029 Blocks ANDA approval based on NCE protection
Orphan-drug exclusivity 2031 Protects the approved orphan indication
Composition and use patents Potentially early-to-late 2030s May delay or complicate generic launch
Pediatric exclusivity Possible six-month extension Depends on FDA-requested pediatric studies
Formulation or method patents Potentially later than core protection May support narrower litigation positions

A generic could seek approval through a Paragraph IV certification before patent expiration. That would create potential litigation and a 30-month stay if the NDA holder filed suit within the statutory period. A generic launch before final patent expiry would carry litigation and damages risk.

Which companies are challenging vorasidenib?

No major public Paragraph IV challenge should be treated as established without a current FDA Orange Book review and litigation-docket check. The likely future challengers are large generic manufacturers with oncology capabilities, including Teva, Sandoz, Viatris, Sun Pharma, Dr. Reddy's, and Hikma. Their commercial interest will depend on the size of the treated population, remaining patent life, product complexity, and whether the market supports more than one generic entrant.

Vorasidenib is a small-molecule tablet rather than a biologic, so biosimilar competition is not relevant. Competition will come through abbreviated new drug applications, off-label use of alternative IDH inhibitors, and future branded therapies.

What formulations and methods of use protect AG-881?

Vorasidenib is supplied as oral tablets in 10 mg and 40 mg strengths. The principal formulation value is operational rather than technological: once-daily oral dosing supports chronic outpatient treatment and avoids infusion infrastructure.

Potentially relevant patent categories include:

  1. The vorasidenib chemical entity and stereochemical forms.
  2. Pharmaceutical compositions containing vorasidenib.
  3. Methods of treating IDH1- or IDH2-mutant glioma.
  4. Methods of delaying radiation or chemotherapy.
  5. Dosing regimens for chronic administration.
  6. Use in defined molecular subgroups.
  7. Combination treatment with radiotherapy, temozolomide, or other targeted agents.

Method-of-use patents may remain commercially useful after composition patents expire, but their ability to prevent generic substitution depends on claim scope, labeling, physician behavior, and the generic's proposed label. Formulation claims may have weaker practical value if a generic can design around them while producing a therapeutically equivalent tablet.

What development programs remain for vorasidenib?

Vorasidenib's largest development opportunity is expansion beyond the initial post-surgical grade 2 setting.

Key development directions

Development direction Commercial rationale Risk
Pediatric diffuse glioma Supports label expansion and pediatric exclusivity Small patient population
Grade 3 IDH-mutant glioma Enlarges the addressable market Standard-of-care therapy is more intensive
Newly diagnosed disease Moves treatment earlier in the disease course Requires stronger overall-survival and safety evidence
Combination with radiation Could improve disease control May increase neurotoxicity and logistical complexity
Combination with temozolomide Addresses higher-risk disease Competitive with established generic chemotherapy
Recurrent IDH-mutant glioma Expands use after progression More difficult treatment population
Other IDH-mutant solid tumors Broadens the platform Limited clinical validation outside glioma

Agios previously evaluated vorasidenib in multiple IDH-mutant cancers, while Servier controls current global development and commercialization. The clearest near-term opportunity is label expansion within diffuse glioma, not a broad solid-tumor franchise.

How strong is the patent estate for vorasidenib?

The estate is commercially meaningful but not immune to challenge.

Strengths

  • FDA approval in a genetically defined disease creates a clear use case.
  • Orphan-drug exclusivity protects the approved indication through approximately 2031.
  • The drug has composition and method-of-use patent opportunities.
  • Chronic oral treatment can produce recurring revenue before generic entry.
  • Generic development may be less attractive than in large primary-care markets because the patient population is small and molecularly selected.

Weaknesses

  • The treated population is limited.
  • Generic tablets are generally easier to develop than complex biologics.
  • Use patents can be vulnerable to label carve-outs and non-infringing prescribing.
  • The approval is concentrated in grade 2 disease, limiting immediate revenue.
  • Physician adoption depends on long-term data, treatment sequencing, and neurocognitive outcomes.

The overall estate should be viewed as moderate to strong for the initial commercial period, with the most defensible value coming from the approved product, orphan exclusivity, and clinical differentiation rather than from formulation complexity.

How does vorasidenib compare with competing IDH inhibitors?

Vorasidenib has a distinct position because it was designed for central nervous system penetration and demonstrated benefit in nonenhancing IDH-mutant glioma.

Product Company Target Primary position Competitive status
Voranigo Servier IDH1/IDH2 Grade 2 IDH-mutant glioma after surgery FDA-approved
Tibsovo Servier IDH1 AML and cholangiocarcinoma Approved in other diseases
Tazverik Ipsen EZH2 Select hematologic and solid tumors Not a direct IDH competitor
Ivosidenib Servier IDH1 AML, cholangiocarcinoma, other IDH1 settings Potential mechanistic alternative
Enasidenib Bristol Myers Squibb IDH2 Relapsed or refractory AML Not approved for glioma

Ivosidenib and enasidenib are not interchangeable with vorasidenib. Their regulatory indications and central nervous system profiles differ. Off-label use may occur, but vorasidenib has the strongest evidence and regulatory positioning for IDH-mutant diffuse glioma.

What generic entry risks exist for Voranigo?

The most likely launch scenarios are:

Scenario 1: Delayed generic entry

A generic company waits until core patents and orphan exclusivity approach expiry, then launches after a non-infringing label or patent settlement. This scenario preserves branded revenue through approximately 2031 or later.

Scenario 2: Paragraph IV litigation

A generic files an ANDA with a Paragraph IV certification. Servier sues, producing a potential 30-month stay. A settlement could authorize entry before patent expiration while preserving some branded revenue.

Scenario 3: Early launch after patent invalidation

A court invalidates or narrows key patents, allowing launch before the expected expiration date. This is the highest downside scenario for Servier but requires a successful validity or non-infringement challenge.

Scenario 4: Limited substitution

A generic enters but achieves modest share because prescribing remains concentrated among neuro-oncology centers and treatment is linked to molecular testing. This would slow price erosion relative to high-volume chronic medicines.

What is the market projection for vorasidenib?

The addressable U.S. population is likely in the low thousands of treated patients annually, not the tens of thousands typical of large oncology markets. The opportunity depends on incidence, IDH mutation prevalence, eligibility after surgery, diagnosis rates, treatment duration, and access.

Base-case commercial model

Metric Base-case assumption
U.S. eligible patients treated annually at maturity 2,000-3,500
Annual net price assumption $130,000-$170,000
Average treatment duration 18-30 months
Mature U.S. revenue $300 million-$600 million
Global revenue at maturity $500 million-$800 million
Peak sales timing 2029-2033
Generic erosion Begins around early 2030s, subject to patents

The published U.S. list price was reported at approximately $15,500 per 28-day cycle, equivalent to about $201,500 before discounts on a 13-cycle basis. Net revenue will be lower because of commercial rebates, government discounts, patient assistance, and payer negotiations.[3]

Upside case

Peak global sales could exceed $1 billion if:

  • Vorasidenib gains approval in grade 3 disease.
  • Treatment is used earlier and for longer periods.
  • Pediatric adoption expands.
  • European and other international markets reimburse broadly.
  • The company demonstrates a meaningful overall-survival or neurocognitive benefit.
  • Combination studies support use across multiple treatment sequences.

Downside case

Sales could remain below $400 million globally if:

  • The grade 2 market is smaller than expected.
  • Treatment duration is short.
  • Payers impose molecular-testing or step-therapy restrictions.
  • Radiation and chemotherapy remain preferred for higher-risk disease.
  • Safety concerns limit chronic use.
  • Patent challenges accelerate generic entry.

What revenue exposure does Voranigo create for Servier?

Voranigo is strategically important because Servier acquired Agios' oncology portfolio and obtained rights to vorasidenib in the transaction structure. The drug gives Servier a differentiated U.S. oncology asset with recurring oral revenue and limited direct competition.

The commercial concentration creates risk. A meaningful proportion of the product's value is tied to one molecular subgroup and one tumor family. Servier's return will depend on launch execution, diagnostic penetration, international pricing, and successful label expansion.

What litigation and settlement issues should investors monitor?

Key monitoring points include:

  • FDA Orange Book patent listings for Voranigo.
  • ANDA filings with Paragraph IV certifications.
  • District-court complaints filed by Servier.
  • Inter partes review petitions at the Patent Trial and Appeal Board.
  • Settlement agreements that establish an authorized-generic date.
  • Patent-term adjustment and pediatric-study extensions.
  • Label changes affecting grade 3, pediatric, or combination use.
  • Reimbursement decisions by major U.S. payers.
  • Competitor data involving other brain-penetrant IDH inhibitors.

No biosimilar litigation is expected because Voranigo is a small molecule. The relevant legal pathway is ANDA litigation, not the Biologics Price Competition and Innovation Act pathway.

Key Takeaways

  • AG-881 is vorasidenib, marketed as Voranigo by Servier.
  • The FDA approved it on Aug. 6, 2024, for patients aged 12 years and older with grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery.
  • INDIGO showed median progression-free survival of 27.7 months versus 11.1 months with placebo.
  • U.S. orphan exclusivity should protect the approved indication through approximately August 2031.
  • The product has no biosimilar risk; future challenges will come from generic manufacturers.
  • The core commercial market is small but high value, with a base-case global peak-sales range of $500 million to $800 million.
  • Grade 3, pediatric, recurrent-disease, and combination indications are the main upside opportunities.
  • Patent and Paragraph IV developments will determine whether generic entry begins in the early 2030s or earlier.
  • The patent estate is commercially useful but should be analyzed together with Orange Book listings, litigation, and claim scope.

FAQs

Is AG-881 the same drug as vorasidenib?

Yes. AG-881 was the development code for vorasidenib, which is marketed in the United States as Voranigo.

What mutation is required for Voranigo treatment?

Treatment requires a susceptible mutation in IDH1 or IDH2, confirmed through an FDA-authorized diagnostic approach.

Can Voranigo replace radiation and temozolomide?

The approved use is intended for patients after surgery who do not require immediate radiation or chemotherapy. It does not establish that vorasidenib replaces those treatments in higher-risk or grade 3 disease.

Is vorasidenib approved for recurrent glioblastoma?

No. The FDA approval is for grade 2 astrocytoma or oligodendroglioma with susceptible IDH1 or IDH2 mutations after surgery. Glioblastoma is not the approved indication.

What is the main investment risk for Voranigo?

The main risks are the limited molecularly defined market, uncertain treatment duration, dependence on label expansion, reimbursement pressure, and generic or patent challenges beginning around the early 2030s.

References

  1. U.S. Food and Drug Administration. (2024). FDA approves vorasidenib for certain gliomas. https://www.fda.gov
  2. Mellinghoff, I. K., et al. (2023). Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. New England Journal of Medicine, 389(7), 589-601.
  3. Servier. (2024). Servier announces U.S. FDA approval of Voranigo (vorasidenib) tablets for patients with grade 2 astrocytoma or oligodendroglioma. https://www.servier.com
  4. National Cancer Institute. (2024). Vorasidenib and IDH-mutant glioma clinical development information. https://clinicaltrials.gov
  5. U.S. Food and Drug Administration. (2024). Voranigo prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.